Extrawell Pharmaceutical Holdings Limited

SEHK:858 Stock Report

Market Cap: HK$121.9m

Extrawell Pharmaceutical Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Yi Xie

Chief executive officer

HK$1.4m

Total compensation

CEO salary percentage94.9%
CEO tenure11.1yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure13.7yrs

Recent management updates

Recent updates

Extrawell Pharmaceutical Holdings (HKG:858) Shareholders Should Be Cautious Despite Solid Earnings

Dec 24
Extrawell Pharmaceutical Holdings (HKG:858) Shareholders Should Be Cautious Despite Solid Earnings

Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Mar 18
Here's Why Extrawell Pharmaceutical Holdings (HKG:858) Can Afford Some Debt

Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

Dec 01
Extrawell Pharmaceutical Holdings (HKG:858) Is Making Moderate Use Of Debt

We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Aug 04
We Think That There Are Some Issues For Extrawell Pharmaceutical Holdings (HKG:858) Beyond Its Promising Earnings

Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Mar 15
Is Extrawell Pharmaceutical Holdings (HKG:858) Using Debt Sensibly?

Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

Aug 20
Some Shareholders May Object To A Pay Rise For Extrawell Pharmaceutical Holdings Limited's (HKG:858) CEO This Year

CEO Compensation Analysis

How has Yi Xie's remuneration changed compared to Extrawell Pharmaceutical Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

HK$176m

Jun 30 2024n/an/a

HK$6m

Mar 31 2024HK$1mHK$1m

-HK$163m

Dec 31 2023n/an/a

-HK$159m

Sep 30 2023n/an/a

-HK$154m

Jun 30 2023n/an/a

-HK$13m

Mar 31 2023HK$1mHK$1m

HK$129m

Dec 31 2022n/an/a

HK$109m

Sep 30 2022n/an/a

HK$88m

Jun 30 2022n/an/a

HK$109m

Mar 31 2022HK$1mHK$1m

HK$131m

Dec 31 2021n/an/a

HK$12m

Sep 30 2021n/an/a

-HK$107m

Jun 30 2021n/an/a

-HK$114m

Mar 31 2021HK$1mHK$1m

-HK$121m

Dec 31 2020n/an/a

HK$6m

Sep 30 2020n/an/a

HK$133m

Jun 30 2020n/an/a

HK$108m

Mar 31 2020HK$1mHK$1m

HK$83m

Dec 31 2019n/an/a

HK$73m

Sep 30 2019n/an/a

HK$63m

Jun 30 2019n/an/a

HK$63m

Mar 31 2019HK$1mHK$1m

HK$64m

Dec 31 2018n/an/a

HK$51m

Sep 30 2018n/an/a

HK$39m

Jun 30 2018n/an/a

HK$34m

Mar 31 2018HK$1mHK$1m

HK$30m

Compensation vs Market: Yi's total compensation ($USD178.19K) is about average for companies of similar size in the Hong Kong market ($USD230.80K).

Compensation vs Earnings: Yi's compensation has been consistent with company performance over the past year.

CEO

Yi Xie (61 yo)

11.1yrs

Tenure

HK$1,386,000

Compensation

Dr. Yi Xie, Ph.D. serves as the Chief Executive Officer of Extrawell Pharmaceutical Holdings Ltd. Dr. Xie is one of the founders of United Gene group of companies in the PRC. Dr. Xie is responsible for res...

Board Members

NamePositionTenureCompensationOwnership
Yi Xie
Executive Chairman & CEO11.1yrsHK$1.39mno data
Yi Lou
Executive Director16.3yrsHK$557.00kno data
Yong Cheng
Deputy CEO & Executive Director11.1yrsHK$713.00k6.14%
HK$ 7.5m
Yi Guo
Executive Director1.8yrsno datano data
Sau Kuen Wong
Company Secretary & Executive Director16.3yrsHK$940.00kno data
Yumin Mao
Honorary Chairman and Chief Scientific Advisorno datano data7.95%
HK$ 9.7m
Lin Hu Fang
Independent Non-Executive Director24yrsHK$70.00kno data
Song Jin
Independent Non-Executive Director20.3yrsHK$70.00kno data
Li Zeng
Independent Non-Executive Directorless than a yearno datano data

13.7yrs

Average Tenure

61yo

Average Age

Experienced Board: 858's board of directors are seasoned and experienced ( 13.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 01:29
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Extrawell Pharmaceutical Holdings Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hatem AlaaEFG-Hermes Research
Jayaprabha DhavaleVirtua Research Inc.